Supreme Court to directly hear contempt petition-Jail Singh Brothers if found guilty of non payment
The Japanese firm's contempt plea against the Singh brothers seeks recovery of Rs 4,000 crore from them as directed by the Singapore tribunal.
New Delhi: Expressing disappointment over the reply furnished by the Singh Brothers, the Supreme Court has held that the ex Ranbaxy promoters will be sent to jail if they violate the court's order to pay arbitral award amount to the Japanese firm Daichii Sankyo.
The Supreme Court Friday expressed dissatisfaction over the replies filed by former Ranbaxy promoters Malvinder Singh and Shivinder Singh in response to its March 14 direction asking them to submit a concrete plan for paying Rs 4,000 crore to Daiichi Sankyo as directed by a Singapore tribunal.
A bench headed by Chief Justice Ranjan Gogoi said it will now straightaway hear the contempt petition against the Singh brothers for non-payment of arbitral award amount to Japanese firm Daiichi Sankyo and send them to jail if violation of its orders is established.
Also Read: Singh Brothers booked under IPC 420 for Rs 2397 crore fraud
The bench, also comprising Justices Deepak Gupta and Sanjiv Khanna, has now fixed the contempt petition of the Japanese firms against the former Ranbaxy promoters for hearing on April 11.
"You may be owning half of the world but there is no concrete plan as to how the arbitral amount would be realised. You said that somebody owed you Rs 6,000 crore. But this is neither here nor there," the bench said.
The Japanese firm's contempt plea against the Singh brothers seeks recovery of Rs 4,000 crore from them as directed by the Singapore tribunal.
Daiichi had bought Ranbaxy in 2008. Later, it had moved the Singapore arbitration tribunal accusing that the Singh brothers had concealed information that Ranbaxy was facing probe by the US Food and Drug Administration and the Department of Justice, while selling its shares.
Also Read: Malvinder Singh alleges spiritual guru invested Ranbaxy stake sale proceeds to buy real estate
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd